Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Natera Inc. Common Stock — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.96 (market cap $7.03B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.1× Norwegian Cruise Line Holdings Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 69 Days and Natera Inc. Common Stock for 0 Days on average.
| NCLH | NTRA | |
|---|---|---|
Market Cap | $7.03B | $57.03B |
Volume | 12,698,429 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $425.64 |
52-Week Low | $14.12 | $179.42 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $21.85B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.32, down 0.2% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Revenue grew to $9.83B in 2025, with a net income margin of 4.3%. Valuation ratios appear attractive with a P/E of 9.28 and P/S of 0.74. Recent news highlights pricing strategies to boost advance bookings and a $950M senior notes offering.
The outlook is mixed: strong earnings beats and analyst buy consensus (51.35%) support upside to the $20.86 price target, but high debt levels and yield pressure pose risks. Investors should weigh solid fundamentals against industry headwinds and financial leverage.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
